Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...
Hosted on MSN1d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...
Hosted on MSN1d
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Cantor Fitzgerald Reiterates Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...